Table 3 Performance of each marker in predicting disease progression among training and testing cohorts
From: Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer
Marker | Training | Testing | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
AUC | Cut point | NPV | Sens | SPC | PPV | NPV | Sens | SPC | PPV | |
PA-18:0–22:0 | 0.64 | 0.11 | 0.89 | 0.80 | 0.39 | 0.23 | 0.91 | 0.77 | 0.54 | 0.28 |
Apolipoprotein A-IV | 0.49 | − 0.21 | 0.85 | 0.72 | 0.35 | 0.20 | 0.85 | 0.77 | 0.30 | 0.21 |
Tenascin C | 0.51 | − 0.17 | 0.82 | 0.30 | 0.41 | 0.19 | 0.81 | 0.50 | 0.49 | 0.19 |
1-Methyladenosine | 0.59 | 3.98 | 0.87 | 0.76 | 0.37 | 0.22 | 0.80 | 0.59 | 0.38 | 0.18 |